Regulatory T-cell Changes in Patients with Steroid-Resistant Nephrotic Syndrome after Rituximab Therapy
The aim of this study was to investigate the effect of rituximab (RTX) treatment on serum immunoglobulin (Ig) A, G, M levels, and B and CD4+CD25+FoxP3+ [T regulatory (Treg)] cell numbers in children who received RTX therapy with steroid-resistant nephrotic syndrome (SRNS). Twenty-three SRNS children...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2021-01-01
|
| Series: | Saudi Journal of Kidney Diseases and Transplantation |
| Online Access: | http://www.sjkdt.org/article.asp?issn=1319-2442;year=2021;volume=32;issue=4;spage=1028;epage=1033;aulast=Tunçay |
| _version_ | 1819119231090819072 |
|---|---|
| author | Seçil Conkar Tunçay Gülden Hakverdi Özgür Şenol Sevgi Mir |
| author_facet | Seçil Conkar Tunçay Gülden Hakverdi Özgür Şenol Sevgi Mir |
| author_sort | Seçil Conkar Tunçay |
| collection | DOAJ |
| description | The aim of this study was to investigate the effect of rituximab (RTX) treatment on serum immunoglobulin (Ig) A, G, M levels, and B and CD4+CD25+FoxP3+ [T regulatory (Treg)] cell numbers in children who received RTX therapy with steroid-resistant nephrotic syndrome (SRNS). Twenty-three SRNS children who received RTX and 20 healthy children in the control group were included. In this cross-sectional cohort study, 23 children with SRNS levels were determined before and one month after RTX treatment by serum IgA, IgG, IgM, and percentages of CD4+CD25+ FoxP3+ cells and B CD19+ cells by flow cytometry (FASCalibur). RTX was administered at a total of four doses of 375 mg/m2/week. Before RTX treatment, percentages of Treg and IgG values were significantly lower in the SRNS group compared to the control group, respectively (P = 0.001). B-cells were significantly lower one month after RTX treatment than before RTX treatment, respectively (P = 0.001). One month after RTX treatment percentages of Tregs, it was found to be significantly higher than before treatment level (P = 0.001). Seventy percent (11/23) remission was achieved with RTX treatment. RTX treatment not only depletes the number of B-cells in SRNS patients but also causes an increase in the number of percentages of Treg cells. |
| first_indexed | 2024-12-22T06:01:29Z |
| format | Article |
| id | doaj.art-acbeff0e2cba4811afc9aba0aadc934d |
| institution | Directory Open Access Journal |
| issn | 1319-2442 |
| language | English |
| last_indexed | 2024-12-22T06:01:29Z |
| publishDate | 2021-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Saudi Journal of Kidney Diseases and Transplantation |
| spelling | doaj.art-acbeff0e2cba4811afc9aba0aadc934d2022-12-21T18:36:33ZengWolters Kluwer Medknow PublicationsSaudi Journal of Kidney Diseases and Transplantation1319-24422021-01-013241028103310.4103/1319-2442.338276Regulatory T-cell Changes in Patients with Steroid-Resistant Nephrotic Syndrome after Rituximab TherapySeçil Conkar TunçayGülden HakverdiÖzgür ŞenolSevgi MirThe aim of this study was to investigate the effect of rituximab (RTX) treatment on serum immunoglobulin (Ig) A, G, M levels, and B and CD4+CD25+FoxP3+ [T regulatory (Treg)] cell numbers in children who received RTX therapy with steroid-resistant nephrotic syndrome (SRNS). Twenty-three SRNS children who received RTX and 20 healthy children in the control group were included. In this cross-sectional cohort study, 23 children with SRNS levels were determined before and one month after RTX treatment by serum IgA, IgG, IgM, and percentages of CD4+CD25+ FoxP3+ cells and B CD19+ cells by flow cytometry (FASCalibur). RTX was administered at a total of four doses of 375 mg/m2/week. Before RTX treatment, percentages of Treg and IgG values were significantly lower in the SRNS group compared to the control group, respectively (P = 0.001). B-cells were significantly lower one month after RTX treatment than before RTX treatment, respectively (P = 0.001). One month after RTX treatment percentages of Tregs, it was found to be significantly higher than before treatment level (P = 0.001). Seventy percent (11/23) remission was achieved with RTX treatment. RTX treatment not only depletes the number of B-cells in SRNS patients but also causes an increase in the number of percentages of Treg cells.http://www.sjkdt.org/article.asp?issn=1319-2442;year=2021;volume=32;issue=4;spage=1028;epage=1033;aulast=Tunçay |
| spellingShingle | Seçil Conkar Tunçay Gülden Hakverdi Özgür Şenol Sevgi Mir Regulatory T-cell Changes in Patients with Steroid-Resistant Nephrotic Syndrome after Rituximab Therapy Saudi Journal of Kidney Diseases and Transplantation |
| title | Regulatory T-cell Changes in Patients with Steroid-Resistant Nephrotic Syndrome after Rituximab Therapy |
| title_full | Regulatory T-cell Changes in Patients with Steroid-Resistant Nephrotic Syndrome after Rituximab Therapy |
| title_fullStr | Regulatory T-cell Changes in Patients with Steroid-Resistant Nephrotic Syndrome after Rituximab Therapy |
| title_full_unstemmed | Regulatory T-cell Changes in Patients with Steroid-Resistant Nephrotic Syndrome after Rituximab Therapy |
| title_short | Regulatory T-cell Changes in Patients with Steroid-Resistant Nephrotic Syndrome after Rituximab Therapy |
| title_sort | regulatory t cell changes in patients with steroid resistant nephrotic syndrome after rituximab therapy |
| url | http://www.sjkdt.org/article.asp?issn=1319-2442;year=2021;volume=32;issue=4;spage=1028;epage=1033;aulast=Tunçay |
| work_keys_str_mv | AT secilconkartuncay regulatorytcellchangesinpatientswithsteroidresistantnephroticsyndromeafterrituximabtherapy AT guldenhakverdi regulatorytcellchangesinpatientswithsteroidresistantnephroticsyndromeafterrituximabtherapy AT ozgursenol regulatorytcellchangesinpatientswithsteroidresistantnephroticsyndromeafterrituximabtherapy AT sevgimir regulatorytcellchangesinpatientswithsteroidresistantnephroticsyndromeafterrituximabtherapy |